tiprankstipranks
Advertisement
Advertisement
Mineralys Secures Lorundrostat Rights and Major Financing Facility
PremiumCompany AnnouncementsMineralys Secures Lorundrostat Rights and Major Financing Facility
3d ago
Mineralys to repurchase future royalty payments in Tanabe license agreement
Premium
The Fly
Mineralys to repurchase future royalty payments in Tanabe license agreement
3d ago
Buy Rating Reiterated on MLYS as Launch-HTN Data Highlight Lorundrostat’s Efficacy in Resistant CKD Hypertension; $54 Price Target Unchanged
Premium
Ratings
Buy Rating Reiterated on MLYS as Launch-HTN Data Highlight Lorundrostat’s Efficacy in Resistant CKD Hypertension; $54 Price Target Unchanged
5d ago
Mineralys Therapeutics Maps Path After Lorundrostat NDA
PremiumCompany AnnouncementsMineralys Therapeutics Maps Path After Lorundrostat NDA
30d ago
Mineralys Therapeutics price target lowered to $42 from $49 at Goldman Sachs
Premium
The Fly
Mineralys Therapeutics price target lowered to $42 from $49 at Goldman Sachs
1M ago
Mineralys Therapeutics reports Q1 EPS (47c), consensus (44c)
Premium
The Fly
Mineralys Therapeutics reports Q1 EPS (47c), consensus (44c)
1M ago
Mineralys Therapeutics Charts Path After NDA Acceptance
PremiumCompany AnnouncementsMineralys Therapeutics Charts Path After NDA Acceptance
3M ago
Mineralys Therapeutics price target raised to $51 from $46 at BofA
Premium
The Fly
Mineralys Therapeutics price target raised to $51 from $46 at BofA
3M ago
Mineralys Therapeutics reports Q4 EPS (40c), consensus (52c)
Premium
The Fly
Mineralys Therapeutics reports Q4 EPS (40c), consensus (52c)
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100